Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor β/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma.
Sumitomo R, Menju T, Shimazu Y, Toyazaki T, Chiba N, Miyamoto H, Hirayama Y, Nishikawa S, Tanaka S, Yutaka Y, Yamada Y, Nakajima D, Ohsumi A, Hamaji M, Sato A, Yoshizawa A, Huang CL, Haga H, Date H. Sumitomo R, et al. Among authors: toyazaki t. Cancer Sci. 2023 Dec;114(12):4521-4534. doi: 10.1111/cas.15987. Epub 2023 Oct 8. Cancer Sci. 2023. PMID: 37806311 Free PMC article.
A novel cell-based assay for the high-throughput screening of epithelial-mesenchymal transition inhibitors: Identification of approved and investigational drugs that inhibit epithelial-mesenchymal transition.
Ishikawa H, Menju T, Toyazaki T, Miyamoto H, Chiba N, Noguchi M, Tamari S, Miyata R, Yutaka Y, Tanaka S, Yamada Y, Nakajima D, Ohsumi A, Hamaji M, Okuno Y, Date H. Ishikawa H, et al. Among authors: toyazaki t. Lung Cancer. 2023 Jan;175:36-46. doi: 10.1016/j.lungcan.2022.11.015. Epub 2022 Nov 23. Lung Cancer. 2023. PMID: 36450215
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer.
Moriya T, Hamaji M, Yoshizawa A, Miyata R, Noguchi M, Tamari S, Chiba N, Miyamoto H, Toyazaki T, Tanaka S, Yamada Y, Yutaka Y, Nakajima D, Ohsumi A, Menju T, Date H. Moriya T, et al. Among authors: toyazaki t. Interact Cardiovasc Thorac Surg. 2022 Feb 21;34(3):416-423. doi: 10.1093/icvts/ivab283. Interact Cardiovasc Thorac Surg. 2022. PMID: 34652430 Free PMC article.
Nrf2/p‑Fyn/ABCB1 axis accompanied by p‑Fyn nuclear accumulation plays pivotal roles in vinorelbine resistance in non‑small cell lung cancer.
Tamari S, Menju T, Toyazaki T, Miyamoto H, Chiba N, Noguchi M, Ishikawa H, Miyata R, Kayawake H, Tanaka S, Yamada Y, Yutaka Y, Nakajima D, Ohsumi A, Hamaji M, Date H. Tamari S, et al. Among authors: toyazaki t. Oncol Rep. 2022 Oct;48(4):171. doi: 10.3892/or.2022.8386. Epub 2022 Aug 12. Oncol Rep. 2022. PMID: 35959810
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M. Kim YH, et al. Among authors: toyazaki t. Cancer Chemother Pharmacol. 2013 Jun;71(6):1445-51. doi: 10.1007/s00280-013-2142-9. Epub 2013 Mar 27. Cancer Chemother Pharmacol. 2013. PMID: 23532206 Clinical Trial.
14 results